SCHEMBL5541949

SCHEMBL5541949

CCC(=O)N1CCN(CCC=O)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 1/20 0.47
GAA P10253 1/20 0.43
ALDH1A1 P00352 3/20 0.42
BLM P54132 1/20 0.41
HRH2 P25021 1/20 0.39
HRH1 P35367 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
CHRNB3 Q05901 1/20 0.39
CHRNA6 Q15825 1/20 0.39
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36
EPHX2 P34913 2/20 0.36
HSD11B1 P28845 2/20 0.36
MAP1LC3B Q9GZQ8 1/20 0.35
HTR1A P08908 1/20 0.35
HTR7 P34969 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3950507 0.81 PIK3CD (0.50) DRD3ALDH1A1HTR7
SCHEMBL24500534 0.80 DRD3 (0.51) DRD3GAAALDH1A1BLMHRH2
SCHEMBL10076105 0.79 DRD3 (0.50) DRD3GAAALDH1A1BLMHRH2
SCHEMBL7413694 0.77 DRD3 (0.49) DRD3GAAALDH1A1BLMHRH2
SCHEMBL11021059 0.77 DRD3 (0.49) DRD3GAAALDH1A1BLMHRH2
SCHEMBL21051920 0.77 LTA4H (0.39) ALDH1A1MEN1KMT2AHSD11B1HTR1A
SCHEMBL24773181 0.77 HRH2 (0.53) DRD3GAAALDH1A1BLMHRH2
SCHEMBL7413697 0.77 ALOX15 (0.52) DRD3GAAALDH1A1BLMHRH2
SCHEMBL180620 0.77
SCHEMBL20756575 0.77 BLM (0.57) DRD3GAAALDH1A1BLMCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 DRD3 132/4885GAA 4165/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.